Not Tagged
Not Tagged
['cll']
i notice many of our frontline studies in #cll for high risk pts being presented at #ash22 have a young median age (~60yo). with what we saw in the alliance trial (br vs. i vs. ir), i wonder how the ae profile of these combo regimens may differ in our older pts w/high risk dz?
Assistant Professor of Medicine in CLL at Mayo Clinic and lifelong learner with a passion for education, hiking, and cooking. Views expressed are my own.